Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Receives $7.67 Consensus Price Target from Analysts

Shares of Polaryx Therapeutics, Inc. (NASDAQ:PLYX) have earned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $7.6667.

Several research firms recently issued reports on PLYX. Wall Street Zen lowered shares of Polaryx Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Zacks Research upgraded shares of Polaryx Therapeutics to a “hold” rating in a research report on Friday, July 10th. Raymond James Financial began coverage on Polaryx Therapeutics in a research note on Thursday, August 13th. They set a “strong-buy” rating and a $6.00 target price for the company. Weiss Ratings upgraded Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Wednesday, July 1st. Finally, HC Wainwright started coverage on Polaryx Therapeutics in a report on Thursday, July 9th. They set a “buy” rating and a $7.00 price target for the company.

Polaryx Therapeutics Price Performance

PLYX opened at $2.16 on Thursday. Polaryx Therapeutics has a twelve month low of $1.86 and a twelve month high of $48.91. The business’s 50-day moving average price is $2.32. The company has a market capitalization of $107.68 million and a PE ratio of -27.00.

Polaryx Therapeutics (NASDAQ:PLYX) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. Sell-side analysts anticipate that Polaryx Therapeutics will post -0.22 EPS for the current fiscal year.

Insider Transactions at Polaryx Therapeutics

In other Polaryx Therapeutics news, CEO Alex Keun Mo Yang bought 88,453 shares of the firm’s stock in a transaction on Wednesday, May 27th. The shares were purchased at an average price of $4.07 per share, for a total transaction of $360,003.71. Following the completion of the transaction, the chief executive officer directly owned 24,233,249 shares in the company, valued at approximately $98,629,323.43. The trade was a 0.37% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 45.82% of the stock is currently owned by corporate insiders.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.